CLASS ACTION UPDATE for QCOM, FLR, FPI and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, July 24, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
QUALCOMM Incorporated (NASDAQ:QCOM) Class Period: January 31, 2018 - March 12, 2018 Lead Plaintiff Deadline: August 7, 2018
Throughout the class period, QUALCOMM Incorporated allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Qualcomm had secretly filed a unilateral notice with CFIUS in order to frustrate Broadcom’s attempt to acquire the Company; and (2) investors suffered damages as a result of defendants’ wrongful acts and omissions. On March 5, 2018, Broadcom announced that Qualcomm had filed a voluntary request for The Committee on Foreign Investment in the United States to initiate an investigation into Broadcom’s actions. Broadcom referred to this as a “blatant, desperate act by Qualcomm to entrench its incumbent board of directors and prevent its own stockholders from voting for Broadcom’s independent director nominees.”
To learn more about the QCOM class action go to: http://www.zlk.com/pslra-d/qualcomm-investigation?wire=3 or email firstname.lastname@example.org.
Fluor Corporation (NYSE:FLR) Class Period: August 14, 2013 - May 3, 2018 Lead Plaintiff Deadline: July 24, 2018
Fluor Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Fluor’s bidding process for projects related to the construction of gas-fired power generation facilities was flawed; (ii) Fluor had improperly estimated the gas-fire projects; (iii) as a result, Fluor would face craft productivity issues, equipment issues and other execution issues; (iv) Fluor would incur multiple charges impacting quarterly results; and (v) Fluor would ultimately decide to discontinue the pursuit of the gas-fired power market.
To learn more about the FLR class action go to: http://www.zlk.com/pslra-d/fluor-class-action?wire=3 or email email@example.com.
Farmland Partners Inc. (NYSE:FPI) Class Period: May 9, 2017 - July 10, 2018 Lead Plaintiff Deadline: September 10, 2018
Farmland Partners Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Farmland artificially increased its revenues by marking loans to related party tenants; (ii) as a results of the foregoing, Farmland’s Class Period revenues were overstated; and (iii) as a result, Farmland’s public statements were materially false and misleading at all relevant times.
To learn more about the FPI class action go to: http://www.zlk.com/pslra-d/farmland-partners-inc?wire=3 or email firstname.lastname@example.org.
Recro Pharma, Inc. (NASDAQ:REPH) Class Period: July 31, 2017 - May 23, 2018 Lead Plaintiff Deadline: July 30, 2018
Recro Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration (“FDA”) approval; and (2) as a result, Recro Pharma’s public statements were materially false and misleading at all relevant times. On May 24, 2018, Recro Pharma announced that the FDA had declined to approve its New Drug Application (“NDA”) for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug’s analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.
To learn more about the REPH class action go to: http://www.zlk.com/pslra-d/recro-pharma-inc?wire=3 or email email@example.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad Street - 24th FloorNew York, NY 10004 firstname.lastname@example.org Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com